To be the centre of excellence for conducting world-class and creative bio-medical research activities to enhance the knowledge base and contribute towards improving the health care system and social advancement for the people of Pakistan.
To emphasize rigorous research fundamentals while stimulating innovation and providing the highest quality research facilities in the institution.
Establishing a research centre shows that we really see value in bringing scientific evidence and also appreciate the importance of scientific culture. We believe that as long as we continue to work together as a team, we can give the very best of ourselves. We are dedicated to driving impact in critical spheres of health care to create impressive and meaningful breakthroughs and to fostering innovation through partnerships and team works. Al-Shifa Research Centre also prepares an annual research report covering the diverse array of all research activities done by the faculty, students, and trainees of Al-Shifa.
Prof. Dr. Ume Sughra
MBBS, MPH, FCPS (Comm. Med),
FRCP (Glasgow), MCPS-HPE
Director Research, Al-Shifa Research Centre
Professor of Public Health
E-mail: dr_sughra@yahoo.com
Sr. no. | Trial Name | Sponsor | Status | Report |
---|---|---|---|---|
1. | A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial in 18 Years of Age and Above to Determine the Safety and Efficacy of ZF2001, a Recombinant Novel Coronavirus Vaccine (CHO cell) for Prevention of COVID-19 | Anhui Zhifei Longcom Biopharmaceutical Co., Ltd China | On going Published in The New England Journal of Medicine DOI: 10.1056/NEJMoa2202261 |
![]() |
2. | A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine when Administrated in Healthy Subjects aged 6 Months through 47 Months | Seqirus | On going | |
3. | (ALVOEYE) :A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT06 Compared with EU-Eylea® in Subjects with Neovascular (wet) Age-related Macular Degeneration | Alvotech Swiss AG | On going |
Sr. no. | Project Name | Sponsor | Principal Investigator | Status |
---|---|---|---|---|
1. | A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial in 18 Years of Age and Above to Determine the Safety and Efficacy of ZF2001, a Recombinant Novel Coronavirus Vaccine (CHO cell) for Prevention of COVID-19 | Anhui Zhifei Longcom Biopharmaceutical Co., Ltd China | Prof. Dr. Ume Sughra | On going Published in The New England Journal of Medicine DOI: 10.1056/NEJMoa2202261 |
2. | A project by WHO to evaluate the preparedness of public health facilities in Islamabad Capital Territory and Rawalpindi, Pakistan, for managing (potential) CBRN events and development of a standard national tool to evaluate hospital preparedness involving Emergency Departments (ED) as well as EMS providers’ readiness for CBRN events in Pakistan | WHO EMRO, Pakistan | Prof. Dr. Ume Sughra | Completed |
3. | A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine when Administrated in Healthy Subjects aged 6 Months through 47 Months | Seqirus | IQVIA Solutions Pakistan (Pvt) Ltd | On going |
4. | (ALVOEYE) :A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT06 Compared with EU-Eylea® in Subjects with Neovascular (wet) Age-related Macular Degeneration | Alvotech Swiss AG | Prof. Dr. Ume Sughra | On going |
Al-Shifa Trust Eye Hospital, Al-Shifa Research Centre on Thursday hosted the 2nd International Research Conference titled ‘Landscape of Clinical Trials in Pakistan’, focusing on collaboration and integration for the rise of the clinical trial industry in Pakistan.
The conference’s purpose, held at Al-Shifa Eye Hospital, Rawalpindi, was to provide a comprehensive forum for experts and participants from the industry to exchange ideas and present a way forward for the promotion of clinical trial research in Pakistan. Chief guest Prof Dr Muhammad Iqbal Choudhary, Director at the International Centre for Chemical and Biological Sciences (ICCBS), Karachi and Coordinator General COMSTECH, highlighted the importance of promotion of the clinical trial industry which will lead to the development of the indigenous pharmaceutical sector and innovative medical devices shortly.
He pointed out that instead of being a service provider, “We can be innovators in this field with both economic benefits as well as health sector sustainability for our country.” Dr Iqbal said that China had adopted the same model, particularly in its fight against the Covid-19 pandemic.
President Al-Shifa Trust Eye Hospital Maj Gen (r) Rehmat Khan shed light on the performances of the Al-Shifa Research Centre and highlighted the implication of clinical trials. He briefed how the trust worked in bringing the clinical trials industry to Pakistan under Dr Ume Sughra.
President also mentioned services of the trust in recent floods, including a donation of Rs60 million to the flood victims and providing primary medical care through free medical camps.
Dean and Chief of Medical Services Al Shifa Trust Eye Hospital, Prof Dr Wajid Ali Khan, thanked Dr Choudhary for showing the way forward with Al Shifa becoming a clinical trial site as Pakistan was being recognized in the international market for conducting clinical trials, which was previously limited to India in the region. Seasoned researchers, including Prof. Dr Shahzad Ali Khan, VC and Dean Health Services Academy, Islamabad, Prof. Dr Tanwir Khaliq, Vice-Chancellor PIMS Dr Sadia Asim, Director, Dow University of Health Science and Prof Dr Saima Saeed, director Indus Hospital delivered keynote speeches.
President
Al-Shifa Trust Eye Hospital
Dean and Chief of Medical Services
Head of Cornea Department
Al-Shifa Trust Eye Hospital
Principal Investigator of ZF2001 Phase III Clinical Trial
Director Research
Al-Shifa Trust Eye Hospital
Hilal-e-Imtiaz, Sitara-e-Imtiaz, Tamgha-e-Imtiaz
Mustafa (PBUH) Prize Laureate
Distinguished National Professor
UNESCO Chair on Medicinal and Bio-organic Natural
Product Chemistry
Director ICCBS H. E. J Karachi,
Coordinator General COMSTECH Islamabad
Vice Chancellor
Health Services Academy Islamabad
Vice Chancellor
Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad
26-12-2022
An international conference on COVID 19 Phase III Clinical Trials in Pakistan was held at Al Shifa Trust Rawalpindi on Wednesday, December 8th, 2021. It was the first international research conference by Al Shifa Trust. The theme for the research was building research expertise with changing times, research at the forefront of Pandemic. Esteemed decision-makers, researchers, academia faculty and scholars, renowned researchers, and representatives from World Health Organization and Drug Regulatory Authority Pakistan took part in the conference.
The conference was put together to highlight the research opportunities generated as a result of the pandemic in Pakistan and the role of national institutes in becoming a part of global activities to combat the pandemic through research in Pakistan. The paradigm shift from curative to preventive medicine was also discussed by the national and international speakers present at the conference.
We are looking for donors who believe in eye health and a brighter world. Make a donation today, and help us continue the good cause of fighting blindness in Pakistan.
President
Al-Shifa Trust Eye Hospital
Dean and Chief of Medical Services
Head of Cornea Department
Al-Shifa Trust Eye Hospital
Welcome Address and introduction of Al-Shifa Trust Eye Hospital and Establishment of Research Centre
Principal Investigator of ZF2001 Phase III Clinical Trial
Director Research
Al-Shifa Trust Eye Hospital
Topic: COVID-19 Phase III Clinical Trial at Al-Shifa Clinical Trial Site
Vice Chancellor
Health Services Academy Islamabad
Topic: Public Health Response In COVID-19
WHO Representative
Pakistan
Topic: WHO support to Government of Pakistan for COVID-19 Response
Executive Director
NIH Pakistan
Topic: Role of NIH in COVID-19 Response in Pakistan
Vice Chancellor
University of Health Sciences Lahore
President
Pakistan Society of Internal Medicine
Topic: Institutional Experience Of COVID-19 Phase III Trials University Of Health Sciences, Lahore
Chinese Representative
Topic: Anhui Zhifei Longcom Biopharmaceutical Co., Ltd Recombinant COVID-19 Vaccine (CHO Cell), Zifivax®, ZF2001
Ex-Chairman, Clinical Studies Committee & Ex-Director, Pharmacy Services, Drug Regulatory Authority of Pakistan Ex-President, Pharmacy Council of Pakistan
Topic: The Country Situation In Clinical Trials, A Drap Perspective
Head Of Clinical Operations
DRK Pharma Solutions Lahore
Topic: Role Of DRK In Bringing & Conducting Clinical Research To Pakistan
Assistant Professor
School Of Public Health Sciences
University of Waterloo Ontario Canada
Topic: Infodemiology and Infoveillance: An overview
08-12-2021
Al-Shifa Research Centre,
Pakistan Institute Of Ophthalmology (PIO),
Al-Shifa Trust Eye Hospital,
Jhelum Road, Rawalpindi, Pakistan.
Phone: 051-5487821-5 Ext 372
Email: dr_sughra@yahoo.com